rabeprazole has been researched along with Laryngopharyngeal Reflux in 9 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Laryngopharyngeal Reflux: Back flow of gastric contents to the LARYNGOPHARYNX where it comes in contact with tissues of the upper aerodigestive tract. Laryngopharyngeal reflux is an extraesophageal manifestation of GASTROESOPHAGEAL REFLUX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rabeprazole was again significantly effective in patients with positive findings for esophageal reflux (p = 0." | 5.36 | Value of barium swallow studies in predicting the response to rabeprazole in elderly patients with laryngopharyngeal reflux disease and nonerosive reflux disease in particular. ( Kato, T; Kimura, Y; Kishimoto, S; Makino, N; Ohmae, Y; Sugiura, M, 2010) |
| "This study aimed to establish validity and reliability of the Filipino Reflux Symptom Index (FRSI) and to test it among patients with laryngopharyngeal reflux (LPR) before and after 6 months' trial of rabeprazole." | 3.85 | Validity and Reliability of the Filipino Reflux Symptom Index. ( Ambrocio, GMC; Carrillo, RJD; Lapeña, JFF, 2017) |
| "To evaluate the efficacy, safety and tolerability of fixed dose combination of Rabeprazole (enteric-coated, EC) 20 mg + Domperidone (sustained release, SR) 30 mg for treatment of laryngopharyngeal reflux disease (LPRD)." | 3.81 | An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref ( Mukaddam, QI; Naik, M; Semmanaselvan, K, 2015) |
| "Rabeprazole was again significantly effective in patients with positive findings for esophageal reflux (p = 0." | 1.36 | Value of barium swallow studies in predicting the response to rabeprazole in elderly patients with laryngopharyngeal reflux disease and nonerosive reflux disease in particular. ( Kato, T; Kimura, Y; Kishimoto, S; Makino, N; Ohmae, Y; Sugiura, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sezen Goktas, S | 1 |
| Dogan, R | 1 |
| Yenigun, A | 1 |
| Calim, OF | 1 |
| Ozturan, O | 1 |
| Tugrul, S | 1 |
| Semmanaselvan, K | 1 |
| Mukaddam, QI | 1 |
| Naik, M | 1 |
| Lapeña, JFF | 1 |
| Ambrocio, GMC | 1 |
| Carrillo, RJD | 1 |
| Lam, PK | 1 |
| Ng, ML | 1 |
| Cheung, TK | 1 |
| Wong, BY | 1 |
| Tan, VP | 1 |
| Fong, DY | 1 |
| Wei, WI | 1 |
| Wong, BC | 1 |
| Kimura, Y | 1 |
| Sugiura, M | 1 |
| Kato, T | 1 |
| Makino, N | 1 |
| Ohmae, Y | 1 |
| Kishimoto, S | 1 |
| Lee, YS | 1 |
| Choi, SH | 1 |
| Son, YI | 1 |
| Park, YH | 1 |
| Kim, SY | 1 |
| Nam, SY | 1 |
| Wang, AJ | 2 |
| Liang, MJ | 2 |
| Jiang, AY | 2 |
| Lin, JK | 2 |
| Xiao, YL | 2 |
| Peng, S | 2 |
| Chen, J | 2 |
| Wen, WP | 2 |
| Chen, MH | 2 |
| Tsutsui, H | 1 |
| Manabe, N | 1 |
| Uno, M | 1 |
| Imamura, H | 1 |
| Kamada, T | 1 |
| Kusunoki, H | 1 |
| Shiotani, A | 1 |
| Hata, J | 1 |
| Harada, T | 1 |
| Haruma, K | 1 |
4 trials available for rabeprazole and Laryngopharyngeal Reflux
| Article | Year |
|---|---|
A new approach to vocal cord leukoplakia and evaluation of proton pump ınhibitor treatment.
Topics: Adult; Aged; Female; Humans; Laryngopharyngeal Reflux; Laryngoscopy; Leukoplakia; Male; Middle Aged; | 2019 |
Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Humans; Laryngopharyngeal Reflux; Lary | 2010 |
Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female | 2011 |
Esophageal motor dysfunction plays a key role in GERD with globus sensation--analysis of factors promoting resistance to PPI therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Chi-Square Distribution; Drug Resistance; Elec | 2012 |
5 other studies available for rabeprazole and Laryngopharyngeal Reflux
| Article | Year |
|---|---|
An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref
Topics: Adult; Aged; Capsules; Delayed-Action Preparations; Domperidone; Dopamine Antagonists; Female; Human | 2015 |
Validity and Reliability of the Filipino Reflux Symptom Index.
Topics: Adult; Aged; Case-Control Studies; Disability Evaluation; Drug Administration Schedule; Female; Huma | 2017 |
Value of barium swallow studies in predicting the response to rabeprazole in elderly patients with laryngopharyngeal reflux disease and nonerosive reflux disease in particular.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Anti-Ulcer A | 2010 |
Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Anti-Ulcer Agents; Chronic Disease; End | 2012 |
Predictors of acid suppression success in patients with chronic laryngitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Chronic Disease; Endoscopy, Digest | 2012 |